73 results on '"Melaiu O"'
Search Results
2. Characterization of novel 3′untranslated regions and related polymorphisms of the gene NPPC, encoding for the C-type natriuretic peptide
- Author
-
Melaiu, O., Facioni, M. S., Cabiati, M., Caruso, R., Giannessi, D., Landi, S., Gemignani, F., and Del Ry, S.
- Published
- 2013
- Full Text
- View/download PDF
3. MSLN gene silencing has an anti-malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesothelioma (vol 9, e85935, 2014)
- Author
-
Melaiu, O, Stebbing, J, Lombardo, Y, Bracci, E, Uehara, N, Bonotti, A, Cristaudo, A, Foddis, R, Mutti, L, Barale, R, Gemignani, F, Giamas, G, and Landi, S
- Subjects
Multidisciplinary Sciences ,Science & Technology ,General Science & Technology ,MD Multidisciplinary ,Science & Technology - Other Topics - Published
- 2017
4. Correction: MSLN gene silencing has an anti-malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesothelioma (PLoS ONE (2017) 12:6 (e0180317) DOI: 10.1371/journal.pone.0085935)
- Author
-
Melaiu, O, Stebbing, J, Lombardo, Y, Bracci, E, Uehara, N, Bonotti, A, Cristaudo, A, Foddis, R, Mutti, L, Barale, R, Gemignani, F, Giamas, G, and Landi, S
- Subjects
Settore MED/05 - Published
- 2017
5. PO-220 RAN, a novel and promising gene for malignant pleural mesothelioma
- Author
-
Dell’anno, I., primary, Barone, E., additional, Lepori, I., additional, Migliore, L., additional, Agostini, S., additional, Melaiu, O., additional, Poliseno, L., additional, Gemignani, F., additional, and Landi, S., additional
- Published
- 2018
- Full Text
- View/download PDF
6. A Novel Panel of Serum Biomarkers for MPM Diagnosis
- Author
-
Bonotti, A., primary, Foddis, R., additional, Landi, S., additional, Melaiu, O., additional, De Santi, C., additional, Giusti, L., additional, Donadio, E., additional, Ciregia, F., additional, Mazzoni, M. R., additional, Lucacchini, A., additional, Bovenzi, M., additional, Comar, M., additional, Pantani, E., additional, Pistelli, A., additional, and Cristaudo, A., additional
- Published
- 2017
- Full Text
- View/download PDF
7. MSLN gene silencing has an anti-malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesothelioma
- Author
-
Ho, M, Melaiu, O, Stebbing, J, Lombardo, Y, Bracci, E, Uehara, N, Bonotti, A, Cristaudo, A, Foddis, R, Mutti, L, Barale, R, Gemignani, F, Giamas, G, and Landi, S
- Subjects
Mesothelioma ,Pulmonology ,Gene Expression ,lcsh:Medicine ,Settore MED/04 ,Biochemistry ,Lung and Intrathoracic Tumors ,Molecular Genetics ,RNA interference ,Ovarian carcinoma ,Drug Discovery ,Molecular Cell Biology ,Basic Cancer Research ,medicine ,Genetics ,Cancer Genetics ,Gene silencing ,Mesothelin ,lcsh:Science ,Biology ,Cisplatin ,Multidisciplinary ,biology ,lcsh:R ,Cancer ,Computational Biology ,Cancers and Neoplasms ,Pleural Diseases ,medicine.disease ,Molecular biology ,RNA silencing ,Oncology ,Apoptosis ,Cell culture ,Cancer research ,biology.protein ,Medicine ,lcsh:Q ,medicine.drug ,Research Article - Abstract
Genes involved in the carcinogenetic mechanisms underlying malignant pleural mesothelioma (MPM) are still poorly characterized. So far, mesothelin (MSLN) has aroused the most interest. It encodes for a membrane glycoprotein, frequently over-expressed in various malignancies such as MPM, and ovarian and pancreatic cancers. It has been proposed as a diagnostic and immunotherapeutic target with promising results. However, an alternative therapeutic approach seems to rise, whereby synthetic molecules, such as antisense oligonucleotides, could be used to inhibit MSLN activity. To date, such a gene-level inhibition has been attempted in two studies only, both on pancreatic and ovarian carcinoma cell lines, with the use of silencing RNA approaches. With regard to MPM, only one cell line (H2373) has been employed to study the effects of MSLN depletion. Indeed, the knowledge on the role of MSLN in MPM needs expanding. Accordingly, we investigated the expression of MSLN in a panel of three MPM cell lines, i.e., NCI-H28, Mero-14, and IstMes2; one non-MPM cell line was used as reference (Met5A). MSLN knock-down experiments on MSLN-overexpressing cells were also performed through silencing RNA (siRNA) to verify whether previous findings could be generalized to a different set of cell cultures. In agreement with previous studies, transient MSLN-silencing caused decreased proliferation rate and reduced invasive capacity and sphere formation in MSLN-overexpressing Mero-14 cells. Moreover, MSLN-siRNA combined with cisplatin, triggered a marked increase in apoptosis and a decrease in proliferation as compared to cells treated with each agent alone, thereby suggesting a sensitizing effect of siRNA towards cisplatin. In summary, our findings confirm that MSLN should be considered a key molecular target for novel gene-based targeted therapies of cancer.
- Published
- 2014
8. Myocardial infarction activates the expression of cardiometabolic biomarkers in the heart: study in a swine model
- Author
-
Caselli, C., Melaiu, O., Prescimone, T., Cabiati, M., Campan, M., Lionetti, Vincenzo, Del Ry, S., and Giannessi, D.
- Published
- 2010
9. The regulatory roles of phosphatases in cancer
- Author
-
Stebbing, J, primary, Lit, L C, additional, Zhang, H, additional, Darrington, R S, additional, Melaiu, O, additional, Rudraraju, B, additional, and Giamas, G, additional
- Published
- 2013
- Full Text
- View/download PDF
10. ERAP1 promotes Hedgehog-dependent tumorigenesis by controlling USP47-mediated degradation of beta TrCP
- Author
-
Alberto Gulino, Stéphanie Puget, Carlo Capalbo, Daniele Guardavaccaro, Olivier Ayrault, Doriana Fruci, Giuseppe Giannini, Paola Infante, Luca Busino, Mirella Tanori, Laura Di Magno, Diana Bellavia, Ludovica Lospinoso Severini, Miriam Caimano, Flavia Bernardi, Ombretta Melaiu, Enrico De Smaele, Franco Locatelli, Gerry Melino, Lucia Di Marcotullio, Gianluca Canettieri, Julie Talbot, Angelo Peschiaroli, Francesca Bufalieri, Simonetta Pazzaglia, Marta Moretti, Paolo Romania, Bufalieri, F., Infante, P., Bernardi, F., Caimano, M., Romania, P., Moretti, M., Lospinoso Severini, L., Talbot, J., Melaiu, O., Tanori, M., Di Magno, L., Bellavia, D., Capalbo, C., Puget, S., De Smaele, E., Canettieri, G., Guardavaccaro, D., Busino, L., Peschiaroli, A., Pazzaglia, S., Giannini, G., Melino, G., Locatelli, F., Gulino, A., Ayrault, O., Fruci, D., Di Marcotullio, L., Bufalieri, Francesca [0000-0002-9571-318X], Capalbo, Carlo [0000-0001-8445-6782], De Smaele, Enrico [0000-0003-4524-4423], Busino, Luca [0000-0001-6758-9276], Melino, Gerry [0000-0001-9428-5972], Fruci, Doriana [0000-0003-3388-7296], and Apollo - University of Cambridge Repository
- Subjects
animal structures ,ERAP1 ,Hedgehog ,tumorigenesis ,Carcinogenesis ,Molecular biology ,Science ,Regulator ,General Physics and Astronomy ,medicine.disease_cause ,medulloblastoma ,Aminopeptidases ,USP47 ,General Biochemistry, Genetics and Molecular Biology ,Article ,Minor Histocompatibility Antigens ,Mice ,Ubiquitin ,ubiquitin ,medicine ,ERAP ,Animals ,Hedgehog Proteins ,E3 ligasi ,lcsh:Science ,Transcription factor ,Tissue homeostasis ,Cancer ,Multidisciplinary ,biology ,Protein Stability ,Settore BIO/11 ,ubiquitin, medulloblastoma, ERAP ,General Chemistry ,beta-Transducin Repeat-Containing Proteins ,Ubiquitin ligase ,Cell biology ,Settore MED/38 - PEDIATRIA GENERALE E SPECIALISTICA ,Proteolysis ,biology.protein ,NIH 3T3 Cells ,lcsh:Q ,Ubiquitin-Specific Proteases ,Signal transduction ,Signal Transduction - Abstract
The Hedgehog (Hh) pathway is essential for embryonic development and tissue homeostasis. Aberrant Hh signaling may occur in a wide range of human cancers, such as medulloblastoma, the most common brain malignancy in childhood. Here, we identify endoplasmic reticulum aminopeptidase 1 (ERAP1), a key regulator of innate and adaptive antitumor immune responses, as a previously unknown player in the Hh signaling pathway. We demonstrate that ERAP1 binds the deubiquitylase enzyme USP47, displaces the USP47-associated βTrCP, the substrate-receptor subunit of the SCFβTrCP ubiquitin ligase, and promotes βTrCP degradation. These events result in the modulation of Gli transcription factors, the final effectors of the Hh pathway, and the enhancement of Hh activity. Remarkably, genetic or pharmacological inhibition of ERAP1 suppresses Hh-dependent tumor growth in vitro and in vivo. Our findings unveil an unexpected role for ERAP1 in cancer and indicate ERAP1 as a promising therapeutic target for Hh-driven tumors., ERAP1 is an endoplasmic reticulum aminopeptidase that trims MHC Class-I peptides for antigen presentation. Here, the authors show that ERAP1 enhances Hedgehog signalling by sequestering USP47 from βTrCP and promoting tumorigenesis through βTrCP degradation and increased Gli protein stability.
- Published
- 2019
11. A Novel Panel of Serum Biomarkers for MPM Diagnosis
- Author
-
Massimo Bovenzi, Federica Ciregia, Manola Comar, Laura Giusti, C. De Santi, E Pantani, Alfonso Cristaudo, Maria Rosa Mazzoni, A Bonotti, Elena Donadio, Rudy Foddis, Ombretta Melaiu, Pistelli A, Stefano Landi, Antonio Lucacchini, Bonotti, A., Foddis, R., Landi, S., Melaiu, O., De Santi, C., Giusti, L., Donadio, E., Ciregia, F., Mazzoni, M. R., Lucacchini, A., Bovenzi, Massimo, Comar, Manola, Pantani, E., Pistelli, A., and Cristaudo, A.
- Subjects
Male ,Mesothelioma ,0301 basic medicine ,Pathology ,Lung Neoplasms ,Proteome ,Clinical Biochemistry ,Disease ,medicine.disease_cause ,Settore MED/05 ,0302 clinical medicine ,Aged ,Biomarkers, Tumor ,Blood Proteins ,Case-Control Studies ,Female ,Humans ,Middle Aged ,Molecular Biology ,Genetics ,Biochemistry (medical) ,Diagnosis ,Stage (cooking) ,lcsh:R5-920 ,Tumor ,biology ,General Medicine ,Blood proteins ,030220 oncology & carcinogenesis ,lcsh:Medicine (General) ,Research Article ,medicine.medical_specialty ,Article Subject ,Asbestos ,03 medical and health sciences ,medicine ,Mesothelin ,business.industry ,Mesothelioma, Malignant ,Case-control study ,Cancer ,Biomarker ,Biomarkers ,medicine.disease ,030104 developmental biology ,biology.protein ,business - Abstract
Exposure to asbestos is the main cause of malignant pleural mesothelioma (MPM), a highly aggressive cancer of the pleura. Since the only tools for early detection are based on radiological tests, some authors focused on serum markers (i.e., mesothelin). The aim of this study was the evaluation of new serum biomarkers to be used individually or in combination, in order to improve the outcome of patients whose disease would be diagnosed at an earlier stage. Serum and plasma were available from 43 subjects previously exposed to asbestos and 27 MPM patients, all being epithelioid type. All the new markers found differentially expressed in MPM and healthy subjects, by proteomic and genomic approaches, have been validated in the serum by the use of specific ELISA. The combined approach, using tools of genomics and proteomics, is found to be highly innovative for this type of disease and led to the identification of new serum markers in the diagnosis of MPM. These results, if confirmed in a larger series, may have a strong impact in this area, because early detection of this cancer in people at high risk could significantly improve the course of the disease and the clinical approach to an individualized therapy.
- Published
- 2017
12. NK Cell Receptors in Anti-Tumor and Healthy Tissue Protection: Mechanisms and Therapeutic Advances.
- Author
-
Greppi M, De Franco F, Obino V, Rebaudi F, Goda R, Frumento D, Vita G, Baronti C, Melaiu O, Bozzo M, Candiani S, Vellone VG, Papaccio F, Pesce S, and Marcenaro E
- Abstract
Natural Killer (NK) cells are integral to the innate immune system, renowned for their ability to target and eliminate cancer cells without the need for antigen presentation, sparing normal tissues. These cells are crucial in cancer immunosurveillance due to their diverse array of activating and inhibitory receptors that modulate their cytotoxic activity. However, the tumor microenvironment can suppress NK cell function through various mechanisms. Over recent decades, research has focused on overcoming these tumor escape mechanisms. Initially, efforts concentrated on enhancing T cell activity, leading to impressive results with immunotherapeutic approaches aimed at boosting T cell responses. Nevertheless, a substantial number of patients do not benefit from these treatments and continue to seek effective alternatives. In this context, NK cells present a promising avenue for developing new treatments, given their potent cytotoxic capabilities, safety profile, and activity against T cell-resistant tumors, such as those lacking HLA-I expression. Recent advancements in immunotherapy include strategies to restore and amplify NK cell activity through immune checkpoint inhibitors, cytokines, adoptive NK cell therapy, and CAR-NK cell technology. This review provides a comprehensive overview of NK cell receptors, the tumor escape mechanisms that hinder NK cell function, and the evolving field of NK cell-based cancer immunotherapy, highlighting ongoing efforts to develop more effective and targeted cancer treatment strategies., Competing Interests: Declaration of competing interest Federica Papaccio: private institutional research funding from Merck, travel support from Diatech Pharmacogenetics, ESMO Translational Research Fellowship sponsored by Amgen from 2018 to 2020. The other authors declare no conflicts of interest., (Copyright © 2024. Published by Elsevier B.V.)
- Published
- 2024
- Full Text
- View/download PDF
13. Biomarkers Identification in the Microenvironment of Oral Squamous Cell Carcinoma: A Systematic Review of Proteomic Studies.
- Author
-
Pomella S, Melaiu O, Cifaldi L, Bei R, Gargari M, Campanella V, and Barillari G
- Subjects
- Humans, Prognosis, Tumor Microenvironment, Mouth Neoplasms metabolism, Mouth Neoplasms pathology, Mouth Neoplasms diagnosis, Biomarkers, Tumor metabolism, Proteomics methods, Carcinoma, Squamous Cell metabolism, Carcinoma, Squamous Cell pathology, Carcinoma, Squamous Cell diagnosis
- Abstract
An important determinant for oral squamous cell carcinoma (OSCC) onset and outcome is the composition of the tumor microenvironment (TME). Thus, the study of the interactions occurring among cancer cells, immune cells, and cancer-associated fibroblasts within the TME could facilitate the understanding of the mechanisms underlying OSCC development and progression, as well as of its sensitivity or resistance to the therapy. In this context, it must be highlighted that the characterization of TME proteins is enabled by proteomic methodologies, particularly mass spectrometry (MS). Aiming to identify TME protein markers employable for diagnosing and prognosticating OSCC, we have retrieved a total of 119 articles spanning 2001 to 2023, of which 17 have passed the selection process, satisfying all its criteria. We have found a total of 570 proteins detected by MS-based proteomics in the TME of OSCC; among them, 542 are identified by a single study, while 28 are cited by two or more studies. These 28 proteins participate in extracellular matrix remodeling and/or energy metabolism. Here, we propose them as markers that could be used to characterize the TME of OSCC for diagnostic/prognostic purposes. Noteworthy, most of the 28 individuated proteins share one feature: being modulated by the hypoxia that is present in the proliferating OSCC mass.
- Published
- 2024
- Full Text
- View/download PDF
14. Effects of Angiogenic Factors on the Epithelial-to-Mesenchymal Transition and Their Impact on the Onset and Progression of Oral Squamous Cell Carcinoma: An Overview.
- Author
-
Pomella S, Melaiu O, Dri M, Martelli M, Gargari M, and Barillari G
- Subjects
- Humans, Disease Progression, Vascular Endothelial Growth Factor A metabolism, Neovascularization, Pathologic metabolism, Neovascularization, Pathologic pathology, Animals, Angiogenesis Inducing Agents metabolism, Fibroblast Growth Factor 2 metabolism, Signal Transduction, Epithelial-Mesenchymal Transition, Mouth Neoplasms pathology, Mouth Neoplasms metabolism, Carcinoma, Squamous Cell pathology, Carcinoma, Squamous Cell metabolism
- Abstract
High levels of vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF)-2 and angiopoietin (ANG)-2 are found in tissues from oral squamous cell carcinoma (OSCC) and oral potentially malignant disorders (OPMDs). As might be expected, VEGF, FGF-2, and ANG-2 overexpression parallels the development of new blood and lymphatic vessels that nourish the growing OPMDs or OSCCs and provide the latter with metastatic routes. Notably, VEGF, FGF-2, and ANG-2 are also linked to the epithelial-to-mesenchymal transition (EMT), a trans-differentiation process that respectively promotes or exasperates the invasiveness of normal and neoplastic oral epithelial cells. Here, we have summarized published work regarding the impact that the interplay among VEGF, FGF-2, ANG-2, vessel generation, and EMT has on oral carcinogenesis. Results from the reviewed studies indicate that VEGF, FGF-2, and ANG-2 spark either protein kinase B (AKT) or mitogen-activated protein kinases (MAPK), two signaling pathways that can promote both EMT and new vessels' formation in OPMDs and OSCCs. Since EMT and vessel generation are key to the onset and progression of OSCC, as well as to its radio- and chemo-resistance, these data encourage including AKT or MAPK inhibitors and/or antiangiogenic drugs in the treatment of this malignancy., Competing Interests: The authors declare no conflicts of interest.
- Published
- 2024
- Full Text
- View/download PDF
15. The Combination of Bioavailable Concentrations of Curcumin and Resveratrol Shapes Immune Responses While Retaining the Ability to Reduce Cancer Cell Survival.
- Author
-
Focaccetti C, Palumbo C, Benvenuto M, Carrano R, Melaiu O, Nardozi D, Angiolini V, Lucarini V, Kërpi B, Masuelli L, Cifaldi L, and Bei R
- Subjects
- Humans, Resveratrol pharmacology, Cell Survival, Leukocytes, Mononuclear, Polyphenols pharmacology, Immunity, Curcumin pharmacology, Neoplasms drug therapy
- Abstract
The polyphenols Curcumin (CUR) and Resveratrol (RES) are widely described for their antitumoral effects. However, their low bioavailability is a drawback for their use in therapy. The aim of this study was to explore whether CUR and RES, used at a bioavailable concentration, could modulate immune responses while retaining antitumor activity and to determine whether CUR and RES effects on the immune responses of peripheral blood mononuclear cells (PBMCs) and tumor growth inhibition could be improved by their combination. We demonstrate that the low-dose combination of CUR and RES reduced the survival of cancer cell lines but had no effect on the viability of PBMCs. Although following CUR + RES treatment T lymphocytes showed an enhanced activated state, RES counteracted the increased IFN-γ expression induced by CUR in T cells and the polyphenol combination increased IL-10 production by T regulatory cells. On the other hand, the combined treatment enhanced NK cell activity through the up- and downregulation of activating and inhibitory receptors and increased CD68 expression levels on monocytes/macrophages. Overall, our results indicate that the combination of CUR and RES at low doses differentially shapes immune cells while retaining antitumor activity, support the use of this polyphenol combinations in anticancer therapy and suggest its possible application as adjuvant for NK cell-based immunotherapies.
- Published
- 2023
- Full Text
- View/download PDF
16. Two bullets in the gun: combining immunotherapy with chemotherapy to defeat neuroblastoma by targeting adrenergic-mesenchymal plasticity.
- Author
-
D'Amico S, Tempora P, Gragera P, Król K, Melaiu O, De Ioris MA, Locatelli F, and Fruci D
- Subjects
- Child, Humans, Neoplasm Recurrence, Local, Immunotherapy methods, Epigenesis, Genetic, Neuroblastoma genetics
- Abstract
Neuroblastoma (NB) is a childhood tumor that originates in the peripheral sympathetic nervous system and is responsible for 15% of cancer-related deaths in the pediatric population. Despite intensive multimodal treatment, many patients with high-risk NB relapse and develop a therapy-resistant tumor. One of the phenomena related to therapeutic resistance is intratumor heterogeneity resulting from the adaptation of tumor cells in response to different selective environmental pressures. The transcriptional and epigenetic profiling of NB tissue has recently revealed the existence of two distinct cellular identities in the NB, termed adrenergic (ADRN) and mesenchymal (MES), which can spontaneously interconvert through epigenetic regulation. This phenomenon, known as tumor plasticity, has a major impact on cancer pathogenesis. The aim of this review is to describe the peculiarities of these two cell states, and how their plasticity affects the response to current therapeutic treatments, with special focus on the immunogenic potential of MES cells. Furthermore, we will discuss the opportunity to combine immunotherapy with chemotherapy to counteract NB phenotypic interconversion., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 D’Amico, Tempora, Gragera, Król, Melaiu, De Ioris, Locatelli and Fruci.)
- Published
- 2023
- Full Text
- View/download PDF
17. Clinical Feature Ranking Based on Ensemble Machine Learning Reveals Top Survival Factors for Glioblastoma Multiforme.
- Author
-
Cerono G, Melaiu O, and Chicco D
- Abstract
Glioblastoma multiforme (GM) is a malignant tumor of the central nervous system considered to be highly aggressive and often carrying a terrible survival prognosis. An accurate prognosis is therefore pivotal for deciding a good treatment plan for patients. In this context, computational intelligence applied to data of electronic health records (EHRs) of patients diagnosed with this disease can be useful to predict the patients' survival time. In this study, we evaluated different machine learning models to predict survival time in patients suffering from glioblastoma and further investigated which features were the most predictive for survival time. We applied our computational methods to three different independent open datasets of EHRs of patients with glioblastoma: the Shieh dataset of 84 patients, the Berendsen dataset of 647 patients, and the Lammer dataset of 60 patients. Our survival time prediction techniques obtained concordance index (C-index) = 0.583 in the Shieh dataset, C-index = 0.776 in the Berendsen dataset, and C-index = 0.64 in the Lammer dataset, as best results in each dataset. Since the original studies regarding the three datasets analyzed here did not provide insights about the most predictive clinical features for survival time, we investigated the feature importance among these datasets. To this end, we then utilized Random Survival Forests, which is a decision tree-based algorithm able to model non-linear interaction between different features and might be able to better capture the highly complex clinical and genetic status of these patients. Our discoveries can impact clinical practice, aiding clinicians and patients alike to decide which therapy plan is best suited for their unique clinical status., Competing Interests: Conflict of interestThe authors declare no competing interests., (© The Author(s) 2023.)
- Published
- 2023
- Full Text
- View/download PDF
18. Editorial: Cell network in antitumor immunity of pediatric and adult solid tumors.
- Author
-
Pesce S and Melaiu O
- Subjects
- Humans, Adult, Child, T-Lymphocytes, Cytotoxic, Neoplasms
- Abstract
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
- Published
- 2023
- Full Text
- View/download PDF
19. DNAM-1 chimeric receptor-engineered NK cells: a new frontier for CAR-NK cell-based immunotherapy.
- Author
-
Cifaldi L, Melaiu O, Giovannoni R, Benvenuto M, Focaccetti C, Nardozi D, Barillari G, and Bei R
- Subjects
- Humans, Ligands, Immunotherapy, Receptors, Antigen metabolism, Killer Cells, Natural, Neoplasms genetics, Neoplasms therapy
- Abstract
DNAM-1 is a major NK cell activating receptor and, together with NKG2D and NCRs, by binding specific ligands, strongly contributes to mediating the killing of tumor or virus-infected cells. DNAM-1 specifically recognizes PVR and Nectin-2 ligands that are expressed on some virus-infected cells and on a broad spectrum of tumor cells of both hematological and solid malignancies. So far, while NK cells engineered for different antigen chimeric receptors (CARs) or chimeric NKG2D receptor have been extensively tested in preclinical and clinical studies, the use of DNAM-1 chimeric receptor-engineered NK cells has been proposed only in our recent proof-of-concept study and deserves further development. The aim of this perspective study is to describe the rationale for using this novel tool as a new anti-cancer immunotherapy., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Cifaldi, Melaiu, Giovannoni, Benvenuto, Focaccetti, Nardozi, Barillari and Bei.)
- Published
- 2023
- Full Text
- View/download PDF
20. The Combination of Immune Checkpoint Blockade with Tumor Vessel Normalization as a Promising Therapeutic Strategy for Breast Cancer: An Overview of Preclinical and Clinical Studies.
- Author
-
Melaiu O, Vanni G, Portarena I, Pistolese CA, Anemona L, Pomella S, Bei R, Buonomo OC, Roselli M, Mauriello A, and Barillari G
- Subjects
- Humans, Female, Immune Checkpoint Inhibitors therapeutic use, Neovascularization, Pathologic drug therapy, Angiogenesis Inhibitors therapeutic use, Immunotherapy, Tumor Microenvironment, Breast Neoplasms drug therapy, Neoplasms drug therapy
- Abstract
Immune checkpoint inhibitors (ICIs) have a modest clinical activity when administered as monotherapy against breast cancer (BC), the most common malignancy in women. Novel combinatorial strategies are currently being investigated to overcome resistance to ICIs and promote antitumor immune responses in a greater proportion of BC patients. Recent studies have shown that the BC abnormal vasculature is associated with immune suppression in patients, and hampers both drug delivery and immune effector cell trafficking to tumor nests. Thus, strategies directed at normalizing (i.e., at remodeling and stabilizing) the immature, abnormal tumor vessels are receiving much attention. In particular, the combination of ICIs with tumor vessel normalizing agents is thought to hold great promise for the treatment of BC patients. Indeed, a compelling body of evidence indicates that the addition of low doses of antiangiogenic drugs to ICIs substantially improves antitumor immunity. In this review, we outline the impact that the reciprocal interactions occurring between tumor angiogenesis and immune cells have on the immune evasion and clinical progression of BC. In addition, we overview preclinical and clinical studies that are presently evaluating the therapeutic effectiveness of combining ICIs with antiangiogenic drugs in BC patients.
- Published
- 2023
- Full Text
- View/download PDF
21. DNA Damage Response Gene Signature as Potential Treatment Markers for Oral Squamous Cell Carcinoma.
- Author
-
Pomella S, Cassandri M, Melaiu O, Marampon F, Gargari M, Campanella V, Rota R, and Barillari G
- Subjects
- Humans, Squamous Cell Carcinoma of Head and Neck, DNA Damage, Carcinoma, Squamous Cell drug therapy, Carcinoma, Squamous Cell genetics, Carcinoma, Squamous Cell metabolism, Mouth Neoplasms drug therapy, Mouth Neoplasms genetics, Mouth Neoplasms metabolism, Head and Neck Neoplasms
- Abstract
Oral squamous cell carcinoma (OSCC) is a rapidly progressive cancer that often develops resistance against DNA damage inducers, such as radiotherapy and chemotherapy, which are still the standard of care regimens for this tumor. Thus, the identification of biomarkers capable of monitoring the clinical progression of OSCC and its responsiveness to therapy is strongly required. To meet this need, here we have employed Whole Genome Sequencing and RNA-seq data from a cohort of 316 patients retrieved from the TCGA Pan-Cancer Atlas to analyze the genomic and transcriptomic status of the DNA damage response (DDR) genes in OSCC. Then, we correlated the transcriptomic data with the clinical parameters of each patient. Finally, we relied on transcriptomic and drug sensitivity data from the CTRP v2 portal, performing Pearson's correlation analysis to identify putative vulnerabilities of OSCC cell lines correlated with DDR gene expression. Our results indicate that several DDR genes show a high frequency of genomic and transcriptomic alterations and that the expression of some of them correlates with OSCC grading and infection by the human papilloma virus. In addition, we have identified a signature of eight DDR genes (namely CCNB1 , CCNB2 , CDK2 , CDK4 , CHECK1 , E2F1 , FANCD2 , and PRKDC ) that could be predictive for OSCC response to the novel antitumor compounds sorafenib and tipifarnib-P1. Altogether, our data demonstrate that alterations in DDR genes could have an impact on the biology of OSCC. Moreover, here we propose a DDR gene signature whose expression could be predictive of OSCC responsiveness to therapy.
- Published
- 2023
- Full Text
- View/download PDF
22. Combined mitoxantrone and anti-TGFβ treatment with PD-1 blockade enhances antitumor immunity by remodelling the tumor immune landscape in neuroblastoma.
- Author
-
Lucarini V, Melaiu O, D'Amico S, Pastorino F, Tempora P, Scarsella M, Pezzullo M, De Ninno A, D'Oria V, Cilli M, Emionite L, Infante P, Di Marcotullio L, De Ioris MA, Barillari G, Alaggio R, Businaro L, Ponzoni M, Locatelli F, and Fruci D
- Subjects
- Humans, Mice, Animals, Mitoxantrone pharmacology, CD8-Positive T-Lymphocytes, Transforming Growth Factor beta, Cell Line, Tumor, Mice, Transgenic, Tumor Microenvironment, Programmed Cell Death 1 Receptor, Neuroblastoma drug therapy
- Abstract
Background: Poor infiltration of functioning T cells renders tumors unresponsive to checkpoint-blocking immunotherapies. Here, we identified a combinatorial in situ immunomodulation strategy based on the administration of selected immunogenic drugs and immunotherapy to sensitize poorly T-cell-infiltrated neuroblastoma (NB) to the host antitumor immune response., Methods: 975A2 and 9464D NB cell lines derived from spontaneous tumors of TH-MYCN transgenic mice were employed to study drug combinations able of enhancing the antitumor immune response using in vivo and ex vivo approaches. Migration of immune cells towards drug-treated murine-derived organotypic tumor spheroids (MDOTS) were assessed by microfluidic devices. Activation status of immune cells co-cultured with drug-treated MDOTS was evaluated by flow cytometry analysis. The effect of drug treatment on the immune content of subcutaneous or orthotopic tumors was comprehensively analyzed by flow-cytometry, immunohistochemistry and multiplex immunofluorescence. The chemokine array assay was used to detect soluble factors released into the tumor microenvironment. Patient-derived organotypic tumor spheroids (PDOTS) were generated from human NB specimens. Migration and activation status of autologous immune cells to drug-treated PDOTS were performed., Results: We found that treatment with low-doses of mitoxantrone (MTX) recalled immune cells and promoted CD8
+ T and NK cell activation in MDOTS when combined with TGFβ and PD-1 blockade. This combined immunotherapy strategy curbed NB growth resulting in the enrichment of a variety of both lymphoid and myeloid immune cells, especially intratumoral dendritic cells (DC) and IFNγ- and granzyme B-expressing CD8+ T cells and NK cells. A concomitant production of inflammatory chemokines involved in remodelling the tumor immune landscape was also detected. Interestingly, this treatment induced immune cell recruitment against PDOTS and activation of CD8+ T cells and NK cells., Conclusions: Combined treatment with low-dose of MTX and anti-TGFβ treatment with PD-1 blockade improves antitumor immunity by remodelling the tumor immune landscape and overcoming the immunosuppressive microenvironment of aggressive NB., (© 2022. The Author(s).)- Published
- 2022
- Full Text
- View/download PDF
23. Neoadjuvant Treatment as a Risk Factor for Variation of Upper Limb Lymph Node Drainage During Axillary Reverse Mapping in Breast Cancer: A Prospective Observational Study.
- Author
-
Vanni G, Pellicciaro M, Materazzo M, Melaiu O, Longo B, Cervelli V, and Buonomo OC
- Subjects
- Axilla pathology, Coloring Agents, Female, Humans, Ki-67 Antigen, Lymph Node Excision, Lymph Nodes pathology, Lymph Nodes surgery, Neoadjuvant Therapy adverse effects, Risk Factors, Sentinel Lymph Node Biopsy, Breast Neoplasms complications, Breast Neoplasms drug therapy, Breast Neoplasms surgery, Lymphedema etiology
- Abstract
Background/aim: The Axillary Reverse Mapping technique in breast cancer, was adopted in order to minimize the risk of upper limb lymphedema. Currently, there is only limited evidence available regarding its oncological safety. The aim of this study was to evaluate the presence of upper limb nodes in surgical specimens following axillary lymphadenectomy, and its relative predictive relevance., Patients and Methods: All patients undergoing axillary lymphadenectomy were enrolled in the current prospective observational study. Indocyanine green was injected into the ipsilateral arm, followed by the standard axillary surgical procedure. Subsequently, the surgical specimens were examined in order to identify any resected upper limb nodes., Results: Out of 22 patients, 5 (22.7%) exhibited fluorescent nodes in the surgical specimen. At univariate analysis, these patients presented statistically significant differences in terms of neoadjuvant treatment, estrogen receptor (ER), progesterone receptor (PR), Ki67 index and position of fluorescent lymph nodes (p=0.021, p=0.033, p=0.002, p=0.049 and p=0.001, respectively). At multivariate analysis, neoadjuvant chemotherapy and Ki67 index were associated with the risk of resecting fluorescent nodes during a standard lymphadenectomy (p=0.005 and p=0.018, respectively)., Conclusion: Axillary Reverse Mapping should be individually tailored for patients with advanced axillary breast cancer and those undergoing neoadjuvant treatment. Suspected metastases or upper limb nodes identified in unusual positions must always be resected., (Copyright © 2022 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
24. The Multiple Roles of CD147 in the Development and Progression of Oral Squamous Cell Carcinoma: An Overview.
- Author
-
Barillari G, Melaiu O, Gargari M, Pomella S, Bei R, and Campanella V
- Subjects
- Basigin genetics, Basigin metabolism, Humans, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell pathology, Head and Neck Neoplasms, Mouth Neoplasms pathology
- Abstract
Cluster of differentiation (CD)147, also termed extracellular matrix metalloprotease inducer or basigin, is a glycoprotein ubiquitously expressed throughout the human body, the oral cavity included. CD147 actively participates in physiological tissue development or growth and has important roles in reactive processes such as inflammation, immunity, and tissue repair. It is worth noting that deregulated expression and/or activity of CD147 is observed in chronic inflammatory or degenerative diseases, as well as in neoplasms. Among the latter, oral squamous cell carcinoma (OSCC) is characterized by an upregulation of CD147 in both the neoplastic and normal cells constituting the tumor mass. Most interestingly, the expression and/or activity of CD147 gradually increase as healthy oral mucosa becomes inflamed; hyperplastic/dysplastic lesions are then set on, and, eventually, OSCC develops. Based on these findings, here we summarize published studies which evaluate whether CD147 could be employed as a marker to monitor OSCC development and progression. Moreover, we describe CD147-promoted cellular and molecular events which are relevant to oral carcinogenesis, with the aim to provide useful information for assessing whether CD147 may be the target of novel therapeutic approaches directed against OSCC.
- Published
- 2022
- Full Text
- View/download PDF
25. Targeting the antigen processing and presentation pathway to overcome resistance to immune checkpoint therapy.
- Author
-
D'Amico S, Tempora P, Melaiu O, Lucarini V, Cifaldi L, Locatelli F, and Fruci D
- Subjects
- Antigens, Neoplasm, Humans, Immune Checkpoint Inhibitors therapeutic use, Immunotherapy, Antigen Presentation, Neoplasms drug therapy, Neoplasms pathology
- Abstract
Despite the significant clinical advances with the use of immune checkpoint inhibitors (ICIs) in a wide range of cancer patients, response rates to the therapy are variable and do not always result in long-term tumor regression. The development of ICI-resistant disease is one of the pressing issue in clinical oncology, and the identification of new targets and combination therapies is a crucial point to improve response rates and duration. Antigen processing and presentation (APP) pathway is a key element for an efficient response to ICI therapy. Indeed, malignancies that do not express tumor antigens are typically poor infiltrated by T cells and unresponsive to ICIs. Therefore, improving tumor immunogenicity potentially increases the success rate of ICI therapy. In this review, we provide an overview of the key elements of the APP machinery that can be exploited to enhance tumor immunogenicity and increase the efficacy of ICI-based immunotherapy., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 D’Amico, Tempora, Melaiu, Lucarini, Cifaldi, Locatelli and Fruci.)
- Published
- 2022
- Full Text
- View/download PDF
26. News on immune checkpoint inhibitors as immunotherapy strategies in adult and pediatric solid tumors.
- Author
-
Melaiu O, Lucarini V, Giovannoni R, Fruci D, and Gemignani F
- Subjects
- Adolescent, B7 Antigens analysis, B7-H1 Antigen analysis, CTLA-4 Antigen analysis, Child, Child, Preschool, Combined Modality Therapy methods, Humans, Immunologic Factors therapeutic use, Infant, Infant, Newborn, Neoplasms immunology, Programmed Cell Death 1 Receptor analysis, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Biomarkers, Tumor analysis, Immune Checkpoint Inhibitors therapeutic use, Immunotherapy methods, Neoplasms drug therapy
- Abstract
Immune checkpoint inhibitors (ICIs) have shown unprecedented benefits in various adult cancers, and this success has prompted the exploration of ICI therapy even in childhood malignances. Although the use of ICIs as individual agents has achieved disappointing response rates, combinational therapies are likely to promise better results. However, only a subset of patients experienced prolonged clinical effects, thus suggesting the need to identify robust bio-markers that predict individual clinical response or resistance to ICI therapy as the main challenge. In this review, we focus on how the use of ICIs in adult cancers can be translated into pediatric malignances. We discuss the physiological mechanism of action of each IC, including PD-1, PD-L1 and CTLA-4 and the new emerging ones, LAG-3, TIM-3, TIGIT, B7-H3, BTLA and IDO-1, and evaluate their prognostic value in both adult and childhood tumors. Furthermore, we offer an overview of preclinical models and clinical trials currently under investigation to improve the effectiveness of cancer immunotherapies in these patients. Finally, we outline the main predictive factors that influence the efficacy of ICIs, in order to lay the basis for the development of a pan-cancer immunogenomic model, able to direct young patients towards more specific immunotherapy., (Copyright © 2020. Published by Elsevier Ltd.)
- Published
- 2022
- Full Text
- View/download PDF
27. ERAP1 Controls the Interaction of the Inhibitory Receptor KIR3DL1 With HLA-B51:01 by Affecting Natural Killer Cell Function.
- Author
-
D'Amico S, D'Alicandro V, Compagnone M, Tempora P, Guida G, Romania P, Lucarini V, Melaiu O, Falco M, Algeri M, Pende D, Cifaldi L, and Fruci D
- Subjects
- Aminopeptidases antagonists & inhibitors, Aminopeptidases genetics, Antineoplastic Agents pharmacology, Cell Degranulation, Cell Line, Coculture Techniques, Cytotoxicity, Immunologic, Enzyme Inhibitors pharmacology, HLA-B51 Antigen genetics, Humans, Killer Cells, Natural drug effects, Killer Cells, Natural immunology, Minor Histocompatibility Antigens genetics, Neoplasms drug therapy, Neoplasms genetics, Neoplasms immunology, Receptors, KIR3DL1 genetics, Signal Transduction, Aminopeptidases metabolism, HLA-B51 Antigen metabolism, Killer Cells, Natural enzymology, Minor Histocompatibility Antigens metabolism, Neoplasms enzymology, Receptors, KIR3DL1 metabolism
- Abstract
The endoplasmic reticulum aminopeptidase ERAP1 regulates innate and adaptive immune responses by trimming peptides for presentation by major histocompatibility complex (MHC) class I molecules. Previously, we have shown that genetic or pharmacological inhibition of ERAP1 on murine and human tumor cell lines perturbs the engagement of NK cell inhibitory receptors Ly49C/I and Killer-cell Immunoglobulin-like receptors (KIRs), respectively, by their specific ligands (MHC class I molecules), thus leading to NK cell killing. However, the effect of ERAP1 inhibition in tumor cells was highly variable, suggesting that its efficacy may depend on several factors, including MHC class I typing. To identify MHC class I alleles and KIRs that are more sensitive to ERAP1 depletion, we stably silenced ERAP1 expression in human HLA class I-negative B lymphoblastoid cell line 721.221 (referred to as 221) transfected with a panel of KIR ligands (i.e. HLA-B*51:01, -Cw3, -Cw4 and -Cw7), or HLA-A2 which does not bind any KIR, and tested their ability to induce NK cell degranulation and cytotoxicity. No change in HLA class I surface expression was detected in all 221 transfectant cells after ERAP1 depletion. In contrast, CD107a expression levels were significantly increased on NK cells stimulated with 221-B*51:01 cells lacking ERAP1, particularly in the KIR3DL1-positive NK cell subset. Consistently, genetic or pharmacological inhibition of ERAP1 impaired the recognition of HLA-B*51:01 by the YTS NK cell overexpressing KIR3DL1*001, suggesting that ERAP1 inhibition renders HLA-B*51:01 molecules less eligible for binding to KIR3DL1. Overall, these results identify HLA-B*51:01/KIR3DL1 as one of the most susceptible combinations for ERAP1 inhibition, suggesting that individuals carrying HLA-B*51:01-like antigens may be candidates for immunotherapy based on pharmacological inhibition of ERAP1., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 D’Amico, D’Alicandro, Compagnone, Tempora, Guida, Romania, Lucarini, Melaiu, Falco, Algeri, Pende, Cifaldi and Fruci.)
- Published
- 2021
- Full Text
- View/download PDF
28. Quantification of the Immune Content in Neuroblastoma: Deep Learning and Topological Data Analysis in Digital Pathology.
- Author
-
Bussola N, Papa B, Melaiu O, Castellano A, Fruci D, and Jurman G
- Subjects
- Cloud Computing, Deep Learning, Female, Humans, Lymphocytes metabolism, Male, Neural Networks, Computer, Neuroblastoma diagnostic imaging, Image Interpretation, Computer-Assisted methods, Neuroblastoma immunology
- Abstract
We introduce here a novel machine learning (ML) framework to address the issue of the quantitative assessment of the immune content in neuroblastoma (NB) specimens. First, the EUNet, a U-Net with an EfficientNet encoder, is trained to detect lymphocytes on tissue digital slides stained with the CD3 T-cell marker. The training set consists of 3782 images extracted from an original collection of 54 whole slide images (WSIs), manually annotated for a total of 73,751 lymphocytes. Resampling strategies, data augmentation, and transfer learning approaches are adopted to warrant reproducibility and to reduce the risk of overfitting and selection bias. Topological data analysis (TDA) is then used to define activation maps from different layers of the neural network at different stages of the training process, described by persistence diagrams (PD) and Betti curves. TDA is further integrated with the uniform manifold approximation and projection (UMAP) dimensionality reduction and the hierarchical density-based spatial clustering of applications with noise (HDBSCAN) algorithm for clustering, by the deep features, the relevant subgroups and structures, across different levels of the neural network. Finally, the recent TwoNN approach is leveraged to study the variation of the intrinsic dimensionality of the U-Net model. As the main task, the proposed pipeline is employed to evaluate the density of lymphocytes over the whole tissue area of the WSIs. The model achieves good results with mean absolute error 3.1 on test set, showing significant agreement between densities estimated by our EUNet model and by trained pathologists, thus indicating the potentialities of a promising new strategy in the quantification of the immune content in NB specimens. Moreover, the UMAP algorithm unveiled interesting patterns compatible with pathological characteristics, also highlighting novel insights into the dynamics of the intrinsic dataset dimensionality at different stages of the training process. All the experiments were run on the Microsoft Azure cloud platform.
- Published
- 2021
- Full Text
- View/download PDF
29. Drug-repositioning screening identified fludarabine and risedronic acid as potential therapeutic compounds for malignant pleural mesothelioma.
- Author
-
Dell'Anno I, Martin SA, Barbarino M, Melani A, Silvestri R, Bottaro M, Paolicchi E, Corrado A, Cipollini M, Melaiu O, Giordano A, Luzzi L, Gemignani F, and Landi S
- Subjects
- Cell Line, Cell Proliferation drug effects, Cell Survival drug effects, Drug Repositioning, Gene Expression Regulation, Neoplastic drug effects, Humans, Mesothelioma genetics, Mesothelioma metabolism, Pleural Neoplasms genetics, Pleural Neoplasms metabolism, STAT1 Transcription Factor metabolism, Vidarabine pharmacology, Antineoplastic Agents pharmacology, Mesothelioma drug therapy, Pleural Neoplasms drug therapy, Risedronic Acid pharmacology, STAT1 Transcription Factor antagonists & inhibitors, Vidarabine analogs & derivatives
- Abstract
Objectives Malignant pleural mesothelioma (MPM) is an occupational disease mainly due to asbestos exposure. Effective therapies for MPM are lacking, making this tumour type a fatal disease. Materials and Methods In order to meet this need and in view of a future "drug repositioning" approach, here we screened five MPM (Mero-14, Mero-25, IST-Mes2, NCI-H28 and MSTO-211H) and one SV40-immortalized mesothelial cell line (MeT-5A) as a non-malignant model, with a library of 1170 FDA-approved drugs. Results Among several potential compounds, we found that fludarabine (F-araA) and, to a lesser extent, risedronic acid (RIS) were cytotoxic in MPM cells, in comparison to the non-malignant Met-5A cells. In particular, F-araA reduced the proliferation and the colony formation ability of the MPM malignant cells, in comparison to the non-malignant control cells, as demonstrated by proliferation and colony formation assays, in addition to measurement of the phospho-ERK/total-ERK ratio. We have shown that the response to F-araA was not dependent upon the expression of DCK and NT5E enzymes, nor upon their functional polymorphisms (rs11544786 and rs2295890, respectively). Conclusion This drug repositioning screening approach has identified that F-araA could be therapeutically active against MPM cells, in addition to other tumour types, by inhibiting STAT1 expression and nucleic acids synthesis. Further experiments are required to fully investigate this.
- Published
- 2021
- Full Text
- View/download PDF
30. Common gene variants within 3'-untranslated regions as modulators of multiple myeloma risk and survival.
- Author
-
Melaiu O, Macauda A, Sainz J, Calvetti D, Facioni MS, Maccari G, Ter Horst R, Netea MG, Li Y, Grząśko N, Moreno V, Jurczyszyn A, Jerez A, Watek M, Varkonyi J, Garcia-Sanz R, Kruszewski M, Dudziński M, Kadar K, Jacobsen SEH, Mazur G, Andersen V, Rybicka M, Zawirska D, Raźny M, Zaucha JM, Ostrovsky O, Iskierka-Jazdzewska E, Reis RM, Stępień A, Beider K, Nagler A, Druzd-Sitek A, Marques H, Martìnez-Lopez J, Lesueur F, Avet-Loiseau H, Vangsted AJ, Krawczyk-Kulis M, Butrym A, Jamroziak K, Dumontet C, Vogel U, Rymko M, Pelosini M, Subocz E, Szombath G, Sarasquete ME, Silvestri R, Morani F, Landi S, Campa D, Canzian F, and Gemignani F
- Subjects
- Adult, Aged, Case-Control Studies, Female, Gene Expression Regulation, Neoplastic, Gene Frequency, Genotype, Humans, Male, Middle Aged, Multiple Myeloma diagnosis, Polymorphism, Single Nucleotide, RNA, Messenger genetics, RNA, Messenger metabolism, Risk Factors, Survival Analysis, 3' Untranslated Regions genetics, Genetic Predisposition to Disease genetics, Germ-Line Mutation, Multiple Myeloma genetics
- Abstract
We evaluated the association between germline genetic variants located within the 3'-untranlsated region (polymorphic 3'UTR, ie, p3UTR) of candidate genes involved in multiple myeloma (MM). We performed a case-control study within the International Multiple Myeloma rESEarch (IMMEnSE) consortium, consisting of 3056 MM patients and 1960 controls recruited from eight countries. We selected p3UTR of six genes known to act in different pathways relevant in MM pathogenesis, namely KRAS (rs12587 and rs7973623), VEGFA (rs10434), SPP1 (rs1126772), IRF4 (rs12211228) and IL10 (rs3024496). We found that IL10-rs3024496 was associated with increased risk of developing MM and with a worse overall survival of MM patients. The variant allele was assayed in a vector expressing eGFP chimerized with the IL10 3'-UTR and it was found functionally active following transfection in human myeloma cells. In this experiment, the A-allele caused a lower expression of the reporter gene and this was also in agreement with the in vivo expression of mRNA measured in whole blood as reported in the GTEx portal. Overall, these data are suggestive of an effect of the IL10-rs3024496 SNP on the regulation of IL10 mRNA expression and it could have clinical implications for better characterization of MM patients in terms of prognosis., (© 2020 Union for International Cancer Control.)
- Published
- 2021
- Full Text
- View/download PDF
31. Identification of Overexpressed Genes in Malignant Pleural Mesothelioma.
- Author
-
Morani F, Bisceglia L, Rosini G, Mutti L, Melaiu O, Landi S, and Gemignani F
- Subjects
- Female, Humans, Male, Gene Expression Regulation, Neoplastic, Mesothelioma, Malignant genetics, Mesothelioma, Malignant metabolism, Neoplasm Proteins biosynthesis, Neoplasm Proteins genetics, Pleural Neoplasms genetics, Pleural Neoplasms metabolism
- Abstract
Malignant pleural mesothelioma (MPM) is a fatal tumor lacking effective therapies. The characterization of overexpressed genes could constitute a strategy for identifying drivers of tumor progression as targets for novel therapies. Thus, we performed an integrated gene-expression analysis on RNAseq data of 85 MPM patients from TCGA dataset and reference samples from the GEO. The gene list was further refined by using published studies, a functional enrichment analysis, and the correlation between expression and patients' overall survival. Three molecular signatures defined by 15 genes were detected. Seven genes were involved in cell adhesion and extracellular matrix organization, with the others in control of the mitotic cell division or apoptosis inhibition. Using Western blot analyses, we found that ADAMTS1, PODXL, CIT, KIF23, MAD2L1, TNNT1, and TRAF2 were overexpressed in a limited number of cell lines. On the other hand, interestingly, CTHRC1, E-selectin, SPARC, UHRF1, PRSS23, BAG2, and MDK were abundantly expressed in over 50% of the six MPM cell lines analyzed. Thus, these proteins are candidates as drivers for sustaining the tumorigenic process. More studies with small-molecule inhibitors or silencing RNAs are fully justified and need to be undertaken to better evaluate the cancer-driving role of the targets herewith identified.
- Published
- 2021
- Full Text
- View/download PDF
32. ERAP1 and ERAP2 Enzymes: A Protective Shield for RAS against COVID-19?
- Author
-
D'Amico S, Tempora P, Lucarini V, Melaiu O, Gaspari S, Algeri M, and Fruci D
- Subjects
- Age Factors, Aminopeptidases genetics, Antigen Presentation genetics, COVID-19 virology, Female, Humans, Hypertension genetics, Male, Minor Histocompatibility Antigens genetics, Polymorphism, Single Nucleotide, Sex Factors, Virus Internalization, Aminopeptidases metabolism, Angiotensin-Converting Enzyme 2 metabolism, COVID-19 metabolism, Hypertension enzymology, Minor Histocompatibility Antigens metabolism, Renin-Angiotensin System, SARS-CoV-2 metabolism
- Abstract
Patients with coronavirus disease 2019 (COVID-19) have a wide variety of clinical outcomes ranging from asymptomatic to severe respiratory syndrome that can progress to life-threatening lung lesions. The identification of prognostic factors can help to improve the risk stratification of patients by promptly defining for each the most effective therapy to resolve the disease. The etiological agent causing COVID-19 is a new coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that enters cells via the ACE2 receptor. SARS-CoV-2 infection causes a reduction in ACE2 levels, leading to an imbalance in the renin-angiotensin system (RAS), and consequently, in blood pressure and systemic vascular resistance. ERAP1 and ERAP2 are two RAS regulators and key components of MHC class I antigen processing. Their polymorphisms have been associated with autoimmune and inflammatory conditions, hypertension, and cancer. Based on their involvement in the RAS, we believe that the dysfunctional status of ERAP1 and ERAP2 enzymes may exacerbate the effect of SARS-CoV-2 infection, aggravating the symptomatology and clinical outcome of the disease. In this review, we discuss this hypothesis.
- Published
- 2021
- Full Text
- View/download PDF
33. Nutlin-3a Enhances Natural Killer Cell-Mediated Killing of Neuroblastoma by Restoring p53-Dependent Expression of Ligands for NKG2D and DNAM-1 Receptors.
- Author
-
Veneziani I, Infante P, Ferretti E, Melaiu O, Battistelli C, Lucarini V, Compagnone M, Nicoletti C, Castellano A, Petrini S, Ognibene M, Pezzolo A, Di Marcotullio L, Bei R, Moretta L, Pistoia V, Fruci D, Barnaba V, Locatelli F, and Cifaldi L
- Subjects
- Animals, Antigens, Differentiation, T-Lymphocyte biosynthesis, Cell Line, Tumor, Cytotoxicity, Immunologic, Female, Humans, Ligands, Mice, Mice, Inbred NOD, NK Cell Lectin-Like Receptor Subfamily K biosynthesis, Neuroblastoma immunology, Neuroblastoma pathology, Receptors, Natural Killer Cell metabolism, Xenograft Model Antitumor Assays, Antigens, Differentiation, T-Lymphocyte immunology, Imidazoles pharmacology, Killer Cells, Natural immunology, NK Cell Lectin-Like Receptor Subfamily K immunology, Neuroblastoma drug therapy, Piperazines pharmacology, Tumor Suppressor Protein p53 metabolism
- Abstract
In this study, we explored whether Nutlin-3a, a well-known, nontoxic small-molecule compound antagonizing the inhibitory interaction of MDM2 with the tumor suppressor p53, may restore ligands for natural killer (NK) cell-activating receptors (NK-AR) on neuroblastoma cells to enhance the NK cell-mediated killing. Neuroblastoma cell lines were treated with Nutlin-3a, and the expression of ligands for NKG2D and DNAM-1 NK-ARs and the neuroblastoma susceptibility to NK cells were evaluated. Adoptive transfer of human NK cells in a xenograft neuroblastoma-bearing NSG murine model was assessed. Two data sets of neuroblastoma patients were explored to correlate p53 expression with ligand expression. Luciferase assays and chromatin immunoprecipitation analysis of p53 functional binding on PVR promoter were performed. Primary neuroblastoma cells were also treated with Nutlin-3a, and neuroblastoma spheroids obtained from one high-risk patient were assayed for NK-cell cytotoxicity. We provide evidence showing that the Nutlin-3a-dependent rescue of p53 function in neuroblastoma cells resulted in (i) increased surface expression of ligands for NK-ARs, thus rendering neuroblastoma cell lines significantly more susceptible to NK cell-mediated killing; (ii) shrinkage of human neuroblastoma tumor masses that correlated with overall survival upon adoptive transfer of NK cells in neuroblastoma-bearing mice; (iii) and increased expression of ligands in primary neuroblastoma cells and boosting of NK cell-mediated disaggregation of neuroblastoma spheroids. We also found that p53 was a direct transcription factor regulating the expression of PVR ligand recognized by DNAM-1. Our findings demonstrated an immunomodulatory role of Nutlin-3a, which might be prospectively used for a novel NK cell-based immunotherapy for neuroblastoma., (©2020 American Association for Cancer Research.)
- Published
- 2021
- Full Text
- View/download PDF
34. Dendritic Cells: Behind the Scenes of T-Cell Infiltration into the Tumor Microenvironment.
- Author
-
Lucarini V, Melaiu O, Tempora P, D'Amico S, Locatelli F, and Fruci D
- Abstract
Tumor-infiltrating CD8
+ T cells have been shown to play a crucial role in controlling tumor progression. However, the recruitment and activation of these immune cells at the tumor site are strictly dependent on several factors, including the presence of dendritic cells (DCs), the main orchestrators of the antitumor immune responses. Among the various DC subsets, the role of cDC1s has been demonstrated in several preclinical experimental mouse models. In addition, the high density of tumor-infiltrating cDC1s has been associated with improved survival in many cancer patients. The ability of cDC1s to modulate antitumor activity depends on their interaction with other immune populations, such as NK cells. This evidence has led to the development of new strategies aimed at increasing the abundance and activity of cDC1s in tumors, thus providing attractive new avenues to enhance antitumor immunity for both established and novel anticancer immunotherapies. In this review, we provide an overview of the various subsets of DCs, focusing in particular on the role of cDC1s, their ability to interact with other intratumoral immune cells, and their prognostic significance on solid tumors. Finally, we outline key therapeutic strategies that promote the immunogenic functions of DCs in cancer immunotherapy., Competing Interests: The authors declare no conflict of interest.- Published
- 2021
- Full Text
- View/download PDF
35. Cellular and gene signatures of tumor-infiltrating dendritic cells and natural-killer cells predict prognosis of neuroblastoma.
- Author
-
Melaiu O, Chierici M, Lucarini V, Jurman G, Conti LA, De Vito R, Boldrini R, Cifaldi L, Castellano A, Furlanello C, Barnaba V, Locatelli F, and Fruci D
- Subjects
- Adolescent, Adult, B7-H1 Antigen metabolism, Child, Child, Preschool, Cohort Studies, Datasets as Topic, Dendritic Cells immunology, Disease-Free Survival, Female, Humans, Infant, Killer Cells, Natural immunology, Lymphocytes, Tumor-Infiltrating immunology, Male, Middle Aged, Neuroblastoma genetics, Neuroblastoma immunology, Neuroblastoma pathology, Prognosis, Programmed Cell Death 1 Receptor metabolism, RNA-Seq, Sensitivity and Specificity, Survival Rate, T-Lymphocytes immunology, T-Lymphocytes metabolism, Tumor Microenvironment genetics, Tumor Microenvironment immunology, Young Adult, Dendritic Cells metabolism, Killer Cells, Natural metabolism, Lymphocytes, Tumor-Infiltrating metabolism, Neuroblastoma mortality, Transcriptome immunology
- Abstract
Tumor-infiltrating lymphocytes play an essential role in improving clinical outcome of neuroblastoma (NB) patients, but their relationship with other tumor-infiltrating immune cells in the T cell-inflamed tumors remains poorly investigated. Here we show that dendritic cells (DCs) and natural killer (NK) cells are positively correlated with T-cell infiltration in human NB, both at transcriptional and protein levels, and associate with a favorable prognosis. Multiplex imaging displays DC/NK/T cell conjugates in the tumor microenvironment of low-risk NB. Remarkably, this connection is further strengthened by the identification of gene signatures related to DCs and NK cells able to predict survival of NB patients and strongly correlate with the expression of PD-1 and PD-L1. In summary, our findings unveil a key prognostic role of DCs and NK cells and indicate their related gene signatures as promising tools for the identification of clinical biomarkers to better define risk stratification and survival of NB patients.
- Published
- 2020
- Full Text
- View/download PDF
36. Polymorphisms Within the RET Proto-Oncogene and Risk of Sporadic Medullary Thyroid Carcinoma.
- Author
-
Gemignani F, Romei C, Ciampi R, Corrado A, Melaiu O, Figlioli G, Bonotti A, Foddis R, Cristaudo A, Pellegrini G, Vivaldi A, Cipollini M, Landi S, and Elisei R
- Subjects
- Alleles, Case-Control Studies, Female, Gene Frequency, Genetic Association Studies, Genome, Human, Genotype, Haplotypes, Humans, Italy epidemiology, Male, Mutation, Polymorphism, Single Nucleotide, Proto-Oncogene Mas, Quantitative Trait Loci, Risk, Thyroid Gland pathology, Carcinoma, Neuroendocrine genetics, Polymorphism, Genetic, Proto-Oncogene Proteins c-ret genetics, Thyroid Neoplasms genetics
- Abstract
Background: Sporadic medullary thyroid carcinoma (sMTC) is an uncommon neoplasia arising from the calcitonin-producing parafollicular cells of the thyroid. Previous studies evaluated whether single nucleotide polymorphisms (SNPs) within RET (a pivotal proto-oncogene for this disease) are associated with the risk for developing sMTC, but the results are inconclusive. Methods: In this work, we evaluated the association of RET -SNPs c.74-126G>T (rs2565206), p.Gly691Ser (rs1799939, G>A), p.Leu769 = (rs1800861, G>T), p.Ser836 = (rs1800862, C>T), and p.Ser904 = (rs1800863, C>G) (listed in the order of their chromosomal location) with sMTC. This is one of the largest case - control association studies carried out on sMTC, including 585 sMTC cases (negative for germline mutations within RET ), 1529 patients affected by sporadic nonmedullary thyroid carcinoma (sNMTC), and 989 healthy controls, from central and southern Italy and collected in the period 2000-2017. Results: sNMTC patients showed similar genotype and allele frequencies compared with healthy controls. On the other hand, among sMTC patients, the T-allele of p.Leu769 = was less frequent (OR = 0.70 [CI 0.58-0.84], p = 1.9 × 10
-4 ) and rare homozygotes TT showed an OR = 0.32 ([CI 0.17-0.60], p = 2.3 × 10-4 ). Moreover, a statistically significant excess of the haplotype 2 (characterized by the alleles T-G-G-C-C of the listed SNPs) was observed ( p = 3.9 × 10-3 ). The SNPs were not associated with the expression of RET mRNA, that is, they did not exert an effect in cis as quantitative trait locus (cis-eQTL). However, a strong eQTL association was found for p.Leu769 = and the neighboring gene CSGALNACT2 ( p = 9.3 × 10-50 ; effect-size = -0.65), whose function in cancer is unknown. Conclusions: This study shows that specific RET haplotypes, in particular haplotype 2 and the T-allele of p.Leu769 = , are associated with a reduced risk of sMTC in Italians.- Published
- 2020
- Full Text
- View/download PDF
37. Genetically driven CD39 expression shapes human tumor-infiltrating CD8 + T-cell functions.
- Author
-
Gallerano D, Ciminati S, Grimaldi A, Piconese S, Cammarata I, Focaccetti C, Pacella I, Accapezzato D, Lancellotti F, Sacco L, Caronna R, Melaiu O, Fruci D, D'Oria V, Manzi E, Sagnotta A, Parrino C, Coletta D, Peruzzi G, Terenzi V, Battisti A, Cassoni A, Fadda MT, Brozzetti S, Fazzi K, Grazi GL, Valentini V, Chirletti P, Polimeni A, Barnaba V, and Timperi E
- Subjects
- Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Apyrase antagonists & inhibitors, Apyrase genetics, Cells, Cultured, Female, Gene Expression Regulation, Neoplastic immunology, Humans, Immune Checkpoint Inhibitors pharmacology, Immune Checkpoint Inhibitors therapeutic use, Lymphocytes, Tumor-Infiltrating drug effects, Lymphocytes, Tumor-Infiltrating metabolism, Male, Middle Aged, Neoplasms drug therapy, Neoplasms genetics, Neoplasms pathology, Nivolumab pharmacology, Nivolumab therapeutic use, Polymorphism, Single Nucleotide, Primary Cell Culture, T-Lymphocytes, Cytotoxic drug effects, T-Lymphocytes, Cytotoxic metabolism, Antineoplastic Combined Chemotherapy Protocols pharmacology, Apyrase metabolism, Lymphocytes, Tumor-Infiltrating immunology, Neoplasms immunology, T-Lymphocytes, Cytotoxic immunology
- Abstract
In our study, we investigated the role of CD39 on tumor-infiltrating CD8
+ T lymphocytes (CD8+ TILs) in colorectal, head and neck and pancreatic cancers. Partially confirming recent observations correlating the CD39 expression with T-cell exhaustion, we demonstrated a divergent functional activity in CD39+ CD8+ TILs. On the one hand, CD39+ CD8+ TILs (as compared to their CD39- counterparts) produced significantly lower IFN-γ and IL-2 amounts, expressed higher PD-1, and inversely correlated with perforin and granzyme B expression. On the other, they displayed a significantly higher proliferative capacity ex vivo that was inversely correlated with the PD-1 expression. Therefore, CD39+ CD8+ TILs, including those co-expressing the CD103 (a marker of T resident memory [TRM] cells), were defined as partially dysfunctional T cells that correlate with tumor patients with initial progression stages. Interestingly, our results identified for the first time a single nucleotide polymorphism (SNP rs10748643 A>G), as a genetic factor associated with CD39 expression in CD8+ TILs. Finally, we demonstrated that compounds inhibiting CD39-related ATPases improved CD39+ CD8+ T-cell effector function ex vivo, and that CD39+ CD8+ TILs displayed effective suppression function in vitro. Overall these data suggest that the SNP analysis may represent a suitable predictor of CD39+ CD8+ T-cell expression in cancer patients, and propose the modulation of CD39 as a new strategy to restore partially exhausted CD8+ TILs., (© 2020 UICC.)- Published
- 2020
- Full Text
- View/download PDF
38. Impact of Natural Occurring ERAP1 Single Nucleotide Polymorphisms within miRNA-Binding Sites on HCMV Infection.
- Author
-
Melaiu O, D'Amico S, Tempora P, Lucarini V, and Fruci D
- Subjects
- Aminopeptidases chemistry, Aminopeptidases metabolism, Binding Sites, Humans, MicroRNAs metabolism, Minor Histocompatibility Antigens chemistry, Minor Histocompatibility Antigens metabolism, Protein Binding, Aminopeptidases genetics, Cytomegalovirus Infections genetics, Minor Histocompatibility Antigens genetics, Polymorphism, Single Nucleotide
- Abstract
Human cytomegalovirus (HCMV) is a β-herpesvirus that causes serious problems in people with a compromised immune system, whereas it coexists asymptomatically within the host with a healthy immune system. Like other viruses, HCMV has adopted multiples strategies to manipulate the host's immune responses. Among them, expression of viral microRNAs (miRNAs) is one of the most intriguing. HCMV miR-UL112-5p and miR-US4-1 have been found to contribute to immune evasion by targeting the endoplasmic reticulum aminopeptidase 1 ( ERAP1 ), a highly polymorphic key component of antigen processing. The current incomplete picture on the interplay between viral miRNAs and host immunity implies the need to better characterize the host genetic determinants. Naturally occurring single nucleotide polymorphisms (SNPs) within the miRNA binding sites of target genes may affect miRNA-target interactions. In this review, we focus on the relevance of 3' untranslated region (3'UTR) ERAP1 SNPs within miRNA binding sites in modulating miRNA-mRNA interactions and the possible consequent individual susceptibility to HCMV infection. Moreover, we performed an in silico analysis using different bioinformatic algorithms to predict ERAP1 variants with a putative powerful biological function. This evidence provides a basis to deepen the knowledge on how 3'UTR ERAP1 variants may alter the mechanism of action of HCMV miRNAs, in order to develop targeted antiviral therapies.
- Published
- 2020
- Full Text
- View/download PDF
39. EIF4G1 and RAN as Possible Drivers for Malignant Pleural Mesothelioma.
- Author
-
Dell'Anno I, Barbarino M, Barone E, Giordano A, Luzzi L, Bottaro M, Migliore L, Agostini S, Melani A, Melaiu O, Catalano C, Cipollini M, Silvestri R, Corrado A, Gemignani F, and Landi S
- Subjects
- Carcinogenesis drug effects, Carcinogenesis genetics, Cell Line, Tumor, Cell Proliferation drug effects, Cell Proliferation genetics, Epithelium drug effects, Epithelium pathology, Gene Expression Regulation, Neoplastic drug effects, Gene Expression Regulation, Neoplastic genetics, Humans, Mesothelioma, Malignant pathology, Quinazolines pharmacology, RNA, Small Interfering genetics, Small Molecule Libraries pharmacology, beta Karyopherins genetics, Eukaryotic Initiation Factor-4G genetics, Mesothelioma, Malignant genetics, Pleural Neoplasms genetics, Pleural Neoplasms pathology, ran GTP-Binding Protein genetics
- Abstract
For malignant pleural mesothelioma (MPM) novel therapeutic strategies are urgently needed. In a previous study, we identified 51 putative cancer genes over-expressed in MPM tissues and cell lines. Here, we deepened the study on nine of them ( ASS1 , EIF4G1 , GALNT7 , GLUT1 , IGF2BP3 ( IMP3 ), ITGA4 , RAN , SOD1 , and THBS2 ) to ascertain whether they are truly mesothelial cancer driver genes (CDGs) or genes overexpressed in an adaptive response to the tumoral progression ("passenger genes"). Through a fast siRNA-based screening, we evaluated the consequences of gene depletion on migration, proliferation, colony formation capabilities, and caspase activities of four MPM (Mero-14, Mero-25, IST-Mes2, and NCI-H28) and one SV40-immortalized mesothelial cell line (MeT-5A) as a non-malignant model. The depletion of EIF4G1 and RAN significantly reduced cell proliferation and colony formation and increased caspase activity. In particular, the findings for RAN resemble those observed for other types of cancer. Thus, we evaluated the in vitro effects of importazole (IPZ), a small molecule inhibitor of the interaction between RAN and importin-β. We showed that IPZ could have effects similar to those observed following RAN gene silencing. We also found that primary cell lines from one out of three MPM patients were sensitive to IPZ. As EIF4G1 and RAN deserve further investigation with additional in vitro and in vivo studies, they emerged as promising CDGs, suggesting that their upregulation could play a role in mesothelial tumorigenesis and aggressiveness. Furthermore, present data propose the molecular pathways dependent on RAN as a putative pharmacological target for MPM patients in the view of a future personalized medicine.
- Published
- 2020
- Full Text
- View/download PDF
40. Influence of the Tumor Microenvironment on NK Cell Function in Solid Tumors.
- Author
-
Melaiu O, Lucarini V, Cifaldi L, and Fruci D
- Subjects
- Animals, Humans, Immunity, Innate, Neoplasms genetics, Killer Cells, Natural immunology, Neoplasms immunology, Tumor Microenvironment immunology
- Abstract
Natural killer (NK) cells are a population of innate lymphoid cells playing a pivotal role in host immune responses against infection and tumor growth. These cells have a powerful cytotoxic activity orchestrated by an intricate network of inhibitory and activating signals. The importance of NK cells in controlling tumor growth and in mediating a robust anti-metastatic effect has been demonstrated in different experimental mouse cancer models. Consistently, high density of tumor-infiltrating NK cells has been linked with a good prognosis in multiple human solid tumors. However, there are also tumors that appear to be refractory to NK cell-mediated killing for the presence of an immunosuppressive microenvironment affecting NK cell function. Immunotherapeutic strategies aimed at restoring and increasing the cytotoxic activity of NK cells in solid tumors, including the adoptive transfer of NK and CAR-NK cells, are currently employed in preclinical and clinical studies. In this review, we outline recent advances supporting the direct role of NK cells in controlling expansion of solid tumors and their prognostic value in human cancers. We summarize the mechanisms adopted by cancer cells and the tumor microenvironment to affect NK cell function, and finally we evaluate current strategies to augment the antitumor function of NK cells for the treatment of solid tumors., (Copyright © 2020 Melaiu, Lucarini, Cifaldi and Fruci.)
- Published
- 2020
- Full Text
- View/download PDF
41. Role of genetic variations on MHC class I antigen-processing genes in human cancer and viral-mediated diseases.
- Author
-
D'Alicandro V, Romania P, Melaiu O, and Fruci D
- Subjects
- Histocompatibility Antigens Class I immunology, Humans, Antigen Presentation immunology, Genes, MHC Class I immunology, Genetic Variation immunology, Neoplasms immunology, Peptides immunology, T-Lymphocytes, Cytotoxic immunology, Virus Diseases immunology
- Abstract
Cytotoxic T lymphocytes constantly monitor peptide-MHC class I complexes on the cell surface to eliminate transformed and virally infected cells expressing peptides derived from abnormal proteins. The generation of antigenic peptides and their loading on MHC class I molecules is a multistep process involving different molecules that constitute the so-called antigen processing and presentation machinery (APM). To avoid immune-mediated elimination, human tumors and pathogens have adopted different strategies including loss of MHC class I expression and dysregulation of APM genes and proteins. Here, we summarize recent knowledge on genetic variations in APM genes and their association with cancer development and viral-mediated diseases., (Copyright © 2018 Elsevier Ltd. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
42. Functional polymorphism within NUP210 encoding for nucleoporin GP210 is associated with the risk of endometriosis.
- Author
-
Cipollini M, Luisi S, Piomboni P, Luddi A, Landi D, Melaiu O, Figlioli G, Garritano S, Cappelli V, Viganò P, Gemignani F, Petraglia F, and Landi S
- Subjects
- Adolescent, Adult, Case-Control Studies, Endometriosis pathology, Female, Genetic Predisposition to Disease, Genotype, Humans, Severity of Illness Index, Uterine Diseases pathology, Young Adult, Endometriosis genetics, Nuclear Pore Complex Proteins genetics, Polymorphism, Single Nucleotide, Uterine Diseases genetics
- Abstract
Objective: To investigate whether nucleoporin 210 (GP210, encoded by NUP210 gene) is involved in endometriosis., Design: Immunohistofluorescence analysis for assessing whether GP210 is expressed in endometrial tissues from patients and controls; genotyping and case-control study for assessing the association between rs354476 within NUP210 and risk of endometriosis; in vitro luciferase assay for assessing the functional activity of rs354476., Setting: University., Patient(s): Histologically diagnosed cases (n = 175) of endometriosis: minimal or mild (stage I-II) in 48 cases (28%), moderate (stage III) in 69 cases (39%), and severe (stage IV) in 58 cases (33%). Controls (n = 557) were female blood donors collected at Meyer Hospital of Florence., Intervention(s): None., Main Outcome Measure(s): GP210 tissue expression; genotype distribution and risk of endometriosis; in vitro gene expression measurements., Result(s): GP210 had positive nuclear immunohistofluorescence staining in endometrial glandular epithelium. Carriers of the variant allele were associated with increased risks: C/T, odds ratio (OR) 1.83, 95% confidence interval (CI) 1.04-3.21; T/T, OR 2.55, 95% CI 1.36-4.80. In vitro, luciferase assay showed that rs354476 is a bona fide target for hsa-miR-125b-5p., Conclusion(s): Nucleoporin GP210 is involved in endometriosis. Rs354476 polymorphism affects the regulation of NUP210 gene expression by altering the binding with hsa-miR-125b-5p, a microRNA already known as playing an important role for endometriosis. This provides the rationale for the observed increased risk of endometriosis in carriers of the variant allele., (Copyright © 2019 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
43. ERAP1 promotes Hedgehog-dependent tumorigenesis by controlling USP47-mediated degradation of βTrCP.
- Author
-
Bufalieri F, Infante P, Bernardi F, Caimano M, Romania P, Moretti M, Lospinoso Severini L, Talbot J, Melaiu O, Tanori M, Di Magno L, Bellavia D, Capalbo C, Puget S, De Smaele E, Canettieri G, Guardavaccaro D, Busino L, Peschiaroli A, Pazzaglia S, Giannini G, Melino G, Locatelli F, Gulino A, Ayrault O, Fruci D, and Di Marcotullio L
- Subjects
- Aminopeptidases genetics, Aminopeptidases metabolism, Animals, Carcinogenesis genetics, Hedgehog Proteins metabolism, Mice, Minor Histocompatibility Antigens genetics, Minor Histocompatibility Antigens metabolism, NIH 3T3 Cells, Protein Stability, Proteolysis, Signal Transduction, Aminopeptidases physiology, Minor Histocompatibility Antigens physiology, Ubiquitin-Specific Proteases metabolism, beta-Transducin Repeat-Containing Proteins metabolism
- Abstract
The Hedgehog (Hh) pathway is essential for embryonic development and tissue homeostasis. Aberrant Hh signaling may occur in a wide range of human cancers, such as medulloblastoma, the most common brain malignancy in childhood. Here, we identify endoplasmic reticulum aminopeptidase 1 (ERAP1), a key regulator of innate and adaptive antitumor immune responses, as a previously unknown player in the Hh signaling pathway. We demonstrate that ERAP1 binds the deubiquitylase enzyme USP47, displaces the USP47-associated βTrCP, the substrate-receptor subunit of the SCF
βTrCP ubiquitin ligase, and promotes βTrCP degradation. These events result in the modulation of Gli transcription factors, the final effectors of the Hh pathway, and the enhancement of Hh activity. Remarkably, genetic or pharmacological inhibition of ERAP1 suppresses Hh-dependent tumor growth in vitro and in vivo. Our findings unveil an unexpected role for ERAP1 in cancer and indicate ERAP1 as a promising therapeutic target for Hh-driven tumors.- Published
- 2019
- Full Text
- View/download PDF
44. Counter-regulation of regulatory T cells by autoreactive CD8 + T cells in rheumatoid arthritis.
- Author
-
Cammarata I, Martire C, Citro A, Raimondo D, Fruci D, Melaiu O, D'Oria V, Carone C, Peruzzi G, Cerboni C, Santoni A, Sidney J, Sette A, Paroli M, Caccavale R, Milanetti E, Riminucci M, Timperi E, Piconese S, Manzo A, Montecucco C, Scrivo R, Valesini G, Cariani E, and Barnaba V
- Subjects
- Adult, Aged, Aged, 80 and over, Arthritis, Rheumatoid diagnosis, Arthritis, Rheumatoid metabolism, Biomarkers, CD8-Positive T-Lymphocytes metabolism, Disease Susceptibility, Female, Histocompatibility Antigens Class I chemistry, Histocompatibility Antigens Class I immunology, Humans, Immunomodulation, Immunophenotyping, Male, Middle Aged, Severity of Illness Index, T-Cell Antigen Receptor Specificity, T-Lymphocytes, Regulatory metabolism, Arthritis, Rheumatoid immunology, Autoimmunity, CD8-Positive T-Lymphocytes immunology, T-Lymphocytes, Regulatory immunology
- Abstract
The mechanisms whereby autoreactive T cells escape peripheral tolerance establishing thus autoimmune diseases in humans remain an unresolved question. Here, we demonstrate that autoreactive polyfunctional CD8
+ T cells recognizing self-antigens (i.e., vimentin, actin cytoplasmic 1, or non-muscle myosin heavy chain 9 epitopes) with high avidity, counter-regulate Tregs by killing them, in a consistent percentage of rheumatoid arthritis (RA) patients. Indeed, these CD8+ T cells express a phenotype and gene profile of effector (eff) cells and, upon antigen-specific activation, kill Tregs indirectly in an NKG2D-dependent bystander fashion in vitro. This data provides a mechanistic basis for the finding showing that AE-specific (CD107a+ ) CD8+ T killer cells correlate, directly with the disease activity score, and inversely with the percentage of activated Tregs, in both steady state and follow-up studies in vivo. In addition, multiplex immunofluorescence imaging analyses of inflamed synovial tissues in vivo show that a remarkable number of CD8+ T cells express granzyme-B and selectively contact FOXP3+ Tregs, some of which are in an apoptotic state, validating hence the possibility that CD8+ Teff cells can counteract neighboring Tregs within inflamed tissues, by killing them. Alternatively, the disease activity score of a different subset of patients is correlated with the expansion of a peculiar subpopulation of autoreactive low avidity, partially-activated (pa)CD8+ T cells that, despite they conserve the conventional naïve (N) phenotype, produce high levels of tumor necrosis factor (TNF)-α and exhibit a gene expression signature of a progressive activation state. Tregs directly correlate with the expansion of this autoreactive (low avidity) paCD8+ TN cell subset in vivo, and efficiently control their differentiation rather their proliferation in vitro. Interestingly, autoreactive high avidity CD8+ Teff cells or low avidity paCD8+ TN cells are significantly expanded in RA patients who would become non-responders or patients who would become responders to TNF-α inhibitor therapy, respectively. These data provide evidence of a previously undescribed role of such mechanisms in the progression and therapy of RA., (Copyright © 2019 Elsevier Ltd. All rights reserved.)- Published
- 2019
- Full Text
- View/download PDF
45. Tumor-infiltrating T cells and PD-L1 expression in childhood malignant extracranial germ-cell tumors.
- Author
-
Boldrini R, De Pasquale MD, Melaiu O, Chierici M, Jurman G, Benedetti MC, Salfi NC, Castellano A, Collini P, Furlanello C, Pistoia V, Cifaldi L, Terenziani M, and Fruci D
- Abstract
Although pediatric malignant extracranial germ-cell tumors (meGCTs) are among the most chemosensitive solid tumors, a group of patients relapse and die of disease. To identify new markers predicting clinical outcome, we examined the prognostic relevance of tumor-infiltrating T lymphocytes (TILs) and the expression of PD-1 and PD-L1 in a cohort of pediatric meGCTs by in situ immunohistochemistry. MeGCTs were variously infiltrated by T cell-subtypes according to the tumor subtype, tumor location and age at diagnosis. We distinguished three different phenotypes: i) tumors not infiltrated by T cells (immature teratomas and half of the yolk sac tumors), ii) tumors highly infiltrated by CD8
+ T cells expressing PD-1, which identifies activated tumor-reactive T cells (seminomas and dysgerminomas), iii) tumors highly infiltrated by CD8+ T cells within an immunosuppressive tumor microenvironment characterized by CD4+ FOXP3+ Treg cells and PD-L1-expressing tumor cells (embryonal carcinomas, choriocarcinomas and the remaining yolk sac tumors). Tumor subtypes belonging mixed meGCTs were variously infiltrated, suggesting the coexistence of multiple immune microenvironments either facilitating or precluding the entry of T cells. These findings support the hypothesis that TILs influence the development of meGCTs and might be of clinical relevance to improve risk stratification and the treatment of pediatric patients.- Published
- 2018
- Full Text
- View/download PDF
46. The genetic susceptibility in the development of malignant pleural mesothelioma.
- Author
-
Melaiu O, Gemignani F, and Landi S
- Abstract
Malignant pleural mesothelioma (MPM) is a cancer of the pleural cavity whose main risk factor is exposure to asbestos. However, it has been shown that only a minority of exposed people develops MPM. In fact, the incidence among professionally exposed workers was shown to vary between 0.5% and 18.0%. Various hints suggested that other important cofactors could play a role, in particular the genetic susceptibility. Impressive is the case of Cappadocians families exposed to erionite and affected by an "epidemic" of MPM with about half of the inhabitants dying for the disease. However, no results for a "Cappadocia" gene of susceptibility to MPM have been obtained yet and more studies are needed. Among asbestos-exposed workers, several studies reported familial cases of MPM, suggesting that heredity could be important in the tumor development. However, large studies on familial clusters showed only weak increased risks that could be attributable also to indirect exposures in a contaminated household. Moreover, the risk of developing MPM is increased of a limited extent among people exposed to asbestos with a positive history of familial cancers. A particular is represented by carriers of germline mutations within BAP1 gene. In families and in animal models, mutations within BAP1 are strongly predisposing to develop MPM. However, also other types of cancer (such as uveal melanoma) are present, thus BAP1 mutations are considered as responsible for a hereditary form of a multi-cancer syndrome. In any case, among sporadic MPM, the prevalence of germline BAP1 mutations is negligible. Finally, genetic studies highlighted the presence of low-risk susceptibility alleles, such as those within XRCC3, NAT2 or GSTM1 . Two different genome-wide association studies could not find positive associations reaching the genome-wide statistical significance threshold, however, both were concordant in showing a weak signal within the SDK1 gene region. Overall, it could be concluded that, as for other types of sporadic cancers, the susceptibility to develop MPM following asbestos exposure is modulated moderately by the individual genetic background. Further studies on larger series could help in a better characterization of more genes predisposing to MPM, being this tumor a rare disease., Competing Interests: Conflicts of Interest: The authors have no conflicts of interest to declare.
- Published
- 2018
- Full Text
- View/download PDF
47. PD-L1 Is a Therapeutic Target of the Bromodomain Inhibitor JQ1 and, Combined with HLA Class I, a Promising Prognostic Biomarker in Neuroblastoma.
- Author
-
Melaiu O, Mina M, Chierici M, Boldrini R, Jurman G, Romania P, D'Alicandro V, Benedetti MC, Castellano A, Liu T, Furlanello C, Locatelli F, and Fruci D
- Subjects
- Adolescent, Adult, Antigens, CD genetics, Antigens, CD immunology, Azepines administration & dosage, B7-H1 Antigen immunology, Biomarkers, Tumor genetics, Cell Line, Tumor, Child, Child, Preschool, Female, Gene Expression Regulation, Neoplastic drug effects, Genes, MHC Class I immunology, Humans, Infant, Lymphocytes, Tumor-Infiltrating drug effects, Lymphocytes, Tumor-Infiltrating pathology, Male, Middle Aged, Molecular Targeted Therapy, N-Myc Proto-Oncogene Protein immunology, Neuroblastoma drug therapy, Neuroblastoma immunology, Neuroblastoma pathology, Prognosis, Programmed Cell Death 1 Receptor genetics, Proto-Oncogene Proteins c-myc immunology, Triazoles administration & dosage, Lymphocyte Activation Gene 3 Protein, B7-H1 Antigen genetics, Genes, MHC Class I genetics, N-Myc Proto-Oncogene Protein genetics, Neuroblastoma genetics, Proto-Oncogene Proteins c-myc genetics
- Abstract
Purpose: This study sought to evaluate the expression of programmed cell death-ligand-1 (PD-L1) and HLA class I on neuroblastoma cells and programmed cell death-1 (PD-1) and lymphocyte activation gene 3 (LAG3) on tumor-infiltrating lymphocytes to better define patient risk stratification and understand whether this tumor may benefit from therapies targeting immune checkpoint molecules. Experimental Design: In situ IHC staining for PD-L1, HLA class I, PD-1, and LAG3 was assessed in 77 neuroblastoma specimens, previously characterized for tumor-infiltrating T-cell density and correlated with clinical outcome. Surface expression of PD-L1 was evaluated by flow cytometry and IHC in neuroblastoma cell lines and tumors genetically and/or pharmacologically inhibited for MYC and MYCN. A dataset of 477 human primary neuroblastomas from GEO and ArrayExpress databases was explored for PD-L1, MYC, and MYCN correlation. Results: Multivariate Cox regression analysis demonstrated that the combination of PD-L1 and HLA class I tumor cell density is a prognostic biomarker for predicting overall survival in neuroblastoma patients ( P = 0.0448). MYC and MYCN control the expression of PD-L1 in neuroblastoma cells both in vitro and in vivo Consistently, abundance of PD-L1 transcript correlates with MYC expression in primary neuroblastoma. Conclusions: The combination of PD-L1 and HLA class I represents a novel prognostic biomarker for neuroblastoma. Pharmacologic inhibition of MYCN and MYC may be exploited to target PD-L1 and restore an efficient antitumor immunity in high-risk neuroblastoma. Clin Cancer Res; 23(15); 4462-72. ©2017 AACR ., (©2017 American Association for Cancer Research.)
- Published
- 2017
- Full Text
- View/download PDF
48. Identification of a Genetic Variation in ERAP1 Aminopeptidase that Prevents Human Cytomegalovirus miR-UL112-5p-Mediated Immunoevasion.
- Author
-
Romania P, Cifaldi L, Pignoloni B, Starc N, D'Alicandro V, Melaiu O, Li Pira G, Giorda E, Carrozzo R, Bergvall M, Bergström T, Alfredsson L, Olsson T, Kockum I, Seppälä I, Lehtimäki T, Hurme MA, Hengel H, Santoni A, Cerboni C, Locatelli F, D'Amato M, and Fruci D
- Subjects
- 3' Untranslated Regions genetics, Aminopeptidases genetics, CD8-Positive T-Lymphocytes metabolism, Cytomegalovirus Infections enzymology, Cytomegalovirus Infections genetics, Genotype, Humans, MicroRNAs genetics, Minor Histocompatibility Antigens genetics, Multiple Sclerosis enzymology, Multiple Sclerosis genetics, Protein Binding, RNA, Messenger genetics, RNA, Viral genetics, T-Lymphocytes, Cytotoxic metabolism, Aminopeptidases metabolism, Cytomegalovirus genetics, Genetic Variation genetics, MicroRNAs metabolism, Minor Histocompatibility Antigens metabolism
- Abstract
Herein, we demonstrate that HCMV miR-UL112-5p targets ERAP1, thereby inhibiting the processing and presentation of the HCMV pp65
495-503 peptide to specific CTLs. In addition, we show that the rs17481334 G variant, naturally occurring in the ERAP1 3' UTR, preserves ERAP1 from miR-UL112-5p-mediated degradation. Specifically, HCMV miR-UL112-5p binds the 3' UTR of ERAP1 A variant, but not the 3' UTR of ERAP1 G variant, and, accordingly, ERAP1 expression is reduced both at RNA and protein levels only in human fibroblasts homozygous for the A variant. Consistently, HCMV-infected GG fibroblasts were more efficient in trimming viral antigens and being lysed by HCMV-peptide-specific CTLs. Notably, a significantly decreased HCMV seropositivity was detected among GG individuals suffering from multiple sclerosis, a disease model in which HCMV is negatively associated with adult-onset disorder. Overall, our results identify a resistance mechanism to HCMV miR-UL112-5p-based immune evasion strategy with potential implications for individual susceptibility to infection and other diseases., (Copyright © 2017 The Author(s). Published by Elsevier Inc. All rights reserved.)- Published
- 2017
- Full Text
- View/download PDF
49. Correction: MSLN gene silencing has an anti-malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesothelioma.
- Author
-
Melaiu O, Stebbing J, Lombardo Y, Bracci E, Uehara N, Bonotti A, Cristaudo A, Foddis R, Mutti L, Barale R, Gemignani F, Giamas G, and Landi S
- Abstract
[This corrects the article DOI: 10.1371/journal.pone.0085935.].
- Published
- 2017
- Full Text
- View/download PDF
50. Deregulation of miRNAs in malignant pleural mesothelioma is associated with prognosis and suggests an alteration of cell metabolism.
- Author
-
De Santi C, Melaiu O, Bonotti A, Cascione L, Di Leva G, Foddis R, Cristaudo A, Lucchi M, Mora M, Truini A, Tironi A, Murer B, Boldorini R, Cipollini M, Gemignani F, Gasparini P, Mutti L, and Landi S
- Subjects
- Adult, Aged, Aged, 80 and over, Cell Hypoxia, Energy Metabolism, Female, Gene Expression Regulation, Neoplastic, Humans, Male, Mesothelioma, Malignant, Middle Aged, Prognosis, Survival Analysis, Gene Expression Profiling methods, Lung Neoplasms genetics, Mesothelioma genetics, MicroRNAs genetics, Oligonucleotide Array Sequence Analysis methods
- Abstract
Malignant pleural mesothelioma (MPM) is an aggressive human cancer and miRNAs can play a key role for this disease. In order to broaden the knowledge in this field, the miRNA expression was investigated in a large series of MPM to discover new pathways helpful in diagnosis, prognosis and therapy. We employed nanoString nCounter system for miRNA profiling on 105 MPM samples and 10 healthy pleura. The analysis was followed by the validation of the most significantly deregulated miRNAs by RT-qPCR in an independent sample set. We identified 63 miRNAs deregulated in a statistically significant way. MiR-185, miR-197, and miR-299 were confirmed differentially expressed, after validation study. In addition, the results of the microarray analysis corroborated previous findings concerning miR-15b-5p, miR-126-3p, and miR-145-5p. Kaplan-Meier curves were used to explore the association between miRNA expression and overall survival (OS) and identified a 2-miRNA prognostic signature (Let-7c-5p and miR-151a-5p) related to hypoxia and energy metabolism respectively. In silico analyses with DIANA-microT-CDS highlighted 5 putative targets in common between two miRNAs. With the present work we showed that the pattern of miRNAs expression is highly deregulated in MPM and that a 2-miRNA signature can be a new useful tool for prognosis in MPM.
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.